Ligand Pharmaceuticals (LGND) Net Cash Flow (2010 - 2026)

Ligand Pharmaceuticals' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$59.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 136.34% year-over-year to -$59.8 million; the TTM figure through Mar 2026 stood at $65.8 million (up 3538.0% YoY), while the FY2025 annual figure was $100.3 million, up 98.44% from the prior year.
• Net Cash Flow came in at -$59.8 million for Q1 2026 at Ligand Pharmaceuticals, down from $36.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $69.3 million in Q3 2025 to a low of -$60.3 million in Q2 2023.
• A 5-year average of $5.6 million and a median of $3.1 million in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow jumped 1146.58% in 2022 and slumped 637.71% in 2023, its largest moves.
• Ligand Pharmaceuticals' Net Cash Flow stood at $40.9 million in 2022, then plunged by 92.43% to $3.1 million in 2023, then soared by 230.62% to $10.2 million in 2024, then soared by 253.08% to $36.1 million in 2025, then sank by 265.43% to -$59.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$59.8 million, $36.1 million, and $69.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison